Investor Presentaiton

Executive Summary ☐ ☐ ☐ ☐ ☐ Overall performance resilient ex-PO1 ; Core growth rebounding on healthy demand environment in API and FDF business. CDMO business project pipeline scaled up along with expansion of our strategic manufacturing partnerships 2,406 Cr Revenues for H1, declined 23%. Excluding PO, growth was 14% * 356 Cr EBITDA resulted in a margin of 15% with higher upfront expense on resource allocation towards growth projects and new initiatives. Gross margins maintained at very healthy level Continued focus on growth Capex in CDMO division CGT technology collaboration achieved breakthrough innovation - NexCAR19, India's First CAR-T approval, Accelerating pursuit for next generation innovation Published ESG report for FY 2023 highlighting enhanced sustainability strategy and commitments Outlook: FY24 to be a consolidation year. H2 priorities 1) includes Higher capacity utilization across network to support growth acceleration, 2) Scale up of the new Animal health commercial asset and 3) Continuous improvement initiatives 1 FY23 financials information is based on material Purchase Order supplies to Big Pharma, that was completed on Dec-22 5 Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation